+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

UK Indapamide Market 2020-2026

  • PDF Icon


  • July 2020
  • Region: United Kingdom
  • Orion Market Research Private Limited
  • ID: 5145125
UK Indapamide Market Size, Share & Trends Analysis Report by product (1.25 mg and 2.5 mg), By Application (High Blood Pressure, Heart Failure, and Others), and Forecast 2020-2026.

UK indapamide market is estimated to grow significantly at a CAGR of around 2.4% during the forecast period. A significant prevalence of CVDs has been witnessed in the country. According to the British Heart Foundation, more than one-fourth of the fatalities in UK occur due to CVDs, and it is responsible for around 1.6 million fatalities each year. Moreover, more than 7 million people live with one or the other type of heart diseases in UK in 2018. The rise in the aging population is increasing the prevalence rate of CVDs including stroke and other heart diseases. As per the Institute for Health Metrics and Evaluation, around 107,000 new cases of stroke were registered in the country in 2017. According to NHS, the cost incurred to the patients for the treatment of stroke is around $3.8 billion each year and a loss of $5.1 billion due to loss of productivity, disability, and informal care. Therefore, the increasing burden of stroke further raises the demand for indapamide for the preventive treatment in the country that further propels the market growth.

The UK indapamide market is segmented on the basis of product and application. Based on product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held the significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

The companies which are contributing to the growth of the UK indapamide market include Merck KGaA, Sanofi S.A., Mylan N.V., Laboratori Baldacci S.p.A., Sandoz International GmbH, Bioindustria L.I.M. S.p.A. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.

Research Methodology

The market study of the UK indapamide market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for indapamide market players, potential entrants and pharmaceutical companies for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. UK Indapamide Market Research and Analysis by Product
2. UK Indapamide Market Research and Analysis by Application

The Report Covers
  • Comprehensive research methodology of the UK indapamide market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the UK indapamide market.
  • Insights about market determinants which are stimulating the UK indapamide market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. UK Indapamide Market by Product
5.1.1. 1.25 MG
5.1.2. 2.5 MG
5.2. UK Indapamide Market by Application
5.2.1. High Blood Pressure
5.2.2. Heart Failure
5.2.3. Others
6. Company Profiles
6.1. Bioindustria L.I.M. S.p.A.
6.2. Grupo Azevedos
6.3. Krka Group
6.4. Laboratori Baldacci S.p.A.
6.5. Merck KGaA
6.6. Mylan N.V.
6.7. Sandoz International GmbH
6.8. Sanofi S.A.
6.9. Servier Group
6.10. Teva Pharmaceuticals Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bioindustria L.I.M. S.p.A.
  • Grupo Azevedos
  • Krka Group
  • Laboratori Baldacci S.p.A.
  • Merck KGaA
  • Mylan N.V.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Servier Group
  • Teva Pharmaceuticals Industries Ltd.